Luzitin Overview

  • Founded
  • 2005
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $1.73M
Latest Deal Amount
  • Investors
  • 1

Luzitin General Information


Developer of innovative photosensitizing compounds intended to focus on the pursuit of innovative services for photodynamic therapy and photo diagnosis. The company's compounds can be used to treat cancer and other diseases that contribute to human wellness, enabling physicians to routinely practice for the targeted therapy of solid tumors.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Edifício Bluepharma, Rua da Bayer
  • S. Martinho do Bispo
  • Coimbra, 3045-016
  • Portugal
+351 239 000 000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Luzitin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 07-Dec-2010 $1.73M 00.000 Completed Generating Revenue
To view Luzitin’s complete valuation and funding history, request access »

Luzitin Executive Team (5)

Name Title Board Seat Contact Info
Cláudia Silva Ph.D Chief Operating Officer & Deputy Chief Executive Officer
Sérgio Simões Executive Chairman & Chief Executive Officer
Luís Arnaut Ph.D Board Member & Co-Founder
You’re viewing 3 of 5 executive team members. Get the full list »

Luzitin Board Members (5)

Name Representing Role Since
Luís Arnaut Ph.D Self Board Member & Co-Founder 000 0000
Miguel Botto Portugal Ventures Board Member 000 0000
Paulo Barradas Self Board Member 000 0000
Sérgio Simões Luzitin Executive Chairman & Chief Executive Officer 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Luzitin Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Portugal Ventures Venture Capital Minority 000 0000 000000 0
To view Luzitin’s complete investors history, request access »